E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Diabetes Mellitus, Type 2 |
Diabete Mellito di Tipo 2 |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 diabetes |
Diabete Tipo 2 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
E.1.2 | System Organ Class | 100000004861 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the effect on glycaemic control of once weekly insulin icodec in combination with insulin aspart, with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes (T2D) on a basalbolus regimen. This includes comparing the difference in change from baseline in glycosylated haemoglobin (HbA1c) between insulin icodec and insulin glargine after 26 weeks of treatment to a non-inferiority limit of 0.3%. |
Dimostrare l’effetto sul controllo glicemico dell’insulina icodec una volta alla settimana, in combinazione con l’insulina aspart, con o senza farmaci antidiabetici non insulinici, in soggetti con DT2 in regime di trattamento con insulina basale e rapida. Ciò include confrontare la differenza nella variazione dal basale della HbA1c tra insulina icodec e insulina glargine dopo 26 settimane di trattamento, per un limite di non-inferiorità dello 0,3%. |
|
E.2.2 | Secondary objectives of the trial |
To compare safety with once weekly insulin icodec versus once daily insulin glargine, both in combination with insulin aspart, with or without non-insulin anti-diabetic drugs, in subjects with T2D on a basal-bolus regimen. |
Confrontare il parametro della sicurezza dell’insulina icodec assunta una volta alla settimana rispetto all’insulina glargine assunta una volta al giorno, in combinazione con insulina aspart, con o senza farmaci antidiabetici non insulinici, in soggetti con DT2 in regime di trattamento con insulina basale e rapida. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female aged above or equal to 18 years at the time of signing informed consent. - Diagnosed with T2D 180 days or more prior to the day of screening. - HbA1c from 7.0-10.0% (53.0-85.8 mmol/mol) both inclusive at screening confirmed by central laboratory analysis. - Treated with once daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) and 2-4 daily injections of bolus insulin analog (insulin aspart, faster acting insulin aspart, insulin lispro, insulin glulisine) 90 days or more prior to the day of screening with or without any of the following anti-diabetic drugs/regimens with stable doses 90 days or more prior to screening: -Metformin -Sulfonylureas -Meglitinides (glinides) -Dipeptidyl peptidase-4 (DPP-4) inhibitors -Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -Thiazolidinediones -Alpha-glucosidase inhibitors -Oral combination products (for the allowed individual oral antidiabetic drugs) -Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists - Body mass index (BMI) equal to or below 40.0 kg/m^2. |
- Soggetti di sesso maschile o femminile con età pari o superiore ai 18 anni al momento della firma del modulo di consenso informato. - Diagnosi di DT2 =180 giorni prima del giorno dello screening. - HbA1c nell’intervallo 7,0-10,0% (53,0–85,8 mmol/mol), estremi compresi, allo screening confermata da analisi del laboratorio centrale. - Trattamento con insulina basale giornaliera (protamina neutra hangedorn, degludec, detemir, glargine 100 unità/mL, glargine 300 unità/mL) e trattamento da 2 a 4 volte al giorno con insulina prandiale (aspart, aspart ad azione più rapida – faster aspart –, lispro, lispro ad azione più rapida – ultra rapid lispro –, glulisina) = 90 giorni dalla visita di screening, con o senza la seguente terapia antidiabetica con dose stabile = 90 giorni dalla visita di screening: • Metformina • Sulfaniluree • Meglitinidi (glinidi) • Inibitori di DPP-4 • Inibitori di SGLT-2 • Tiazolidinedioni • Inibitori dell’alfa-glucosidasi • Prodotti di combinazione per via orale (per i singoli farmaci antidiabetici orali consentiti) • Agonisti recettoriali del GLP-1 orali o iniettabili - Indice di massa corporea (IMC) =40,0 kg/m2. |
|
E.4 | Principal exclusion criteria |
- Any episodes (as declared by the subject or in the medical records) of diabetic ketoacidosis within 90 days prior to the day of screening. - Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 180 days prior to the day of screening. - Chronic heart failure classified as being in New York Heart Association Class IV at screening. - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids). - Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. |
- Qualsiasi episodio di chetoacidosi diabetica negli ultimi 90 giorni precedenti il giorno dello screening. - Infarto del miocardio, ictus, ricovero per angina pectoris instabile o attacco ischemico transitorio nei 180 giorni precedenti il giorno dello screening. - Insufficienza cardiaca cronica di Classe IV secondo la New York Heart Association allo screening. - Inizio anticipato o variazione (per oltre 14 giorni consecutivi) nell’assunzione di farmaci concomitanti dei quali è nota l’influenza sul peso o sul metabolismo glicemico (ad es. trattamento con orlistat, ormoni tiroidei o corticosteroidi). - Retinopatia o maculopatia diabetica non controllata o potenzialmente instabile, verificata mediante esame del fondo oculare eseguito negli ultimi 90 giorni precedenti lo screening o nell’intervallo di tempo compreso tra lo screening e la randomizzazione. La dilatazione farmacologica della pupilla è un requisito a meno che non venga usata una fotocamera digitale specifica per un esame del fondo oculare senza dilatazione della pupilla. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in HbA1c |
Variazione nella HbA1c (emoglobina glicata) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
From baseline week 0 (V2) to week 26 (V28) |
Dal valore basale (settimana 0, V2) alla settimana 26 (V28) |
|
E.5.2 | Secondary end point(s) |
1. Change in fasting plasma glucose (FPG) 2. Time in target-range 3.9–10.0 mmol/L (70-180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6 3. Number of severe hypoglycaemic episodes (level 3) 4. Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by blood glucose (BG) meter) 5. Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) 6. Time spent below 3.0 mmol/L (54 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6 7. Time spent above 10 mmol/L (180 mg/dL) using continuous glucose monitoring (CGM) system, Dexcom G6 8. Mean weekly insulin dose 9. Change in body weight |
1. variazione della glicemia a digiuno (FPG) 2. Tempo nell'intervallo target 3,9-10,0 mmol / L (70-180 mg/dL) misurato utilizzando il sistema di monitoraggio continuo del glucosio (CGM), Dexcom G6 3. Numero di episodi ipoglicemici gravi (livello 3) 4. Numero di episodi ipoglicemici clinicamente significativi (livello 2) (inferiore a 3,0 mmol/L (54 mg/dL) confermato dal glucometro) 5. Numero di episodi ipoglicemici clinicamente significativi (livello 2) (inferiore a 3,0 mmol/L (54 mg/dL), confermato dal glucometro) o episodi ipoglicemici gravi (livello 3) 6. Tempo trascorso al di sotto di 3,0 mmol/L (54 mg/dL) utilizzando il sistema di monitoraggio continuo del glucosio (CGM), Dexcom G6 7. Tempo trascorso al di sopra di 10 mmol/L (180 mg/dL) utilizzando il sistema di monitoraggio continuo del glucosio (CGM), Dexcom G6 8. Dose settimanale media di insulina 9. Variazione del peso corporeo |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. From baseline week 0 (V2) to week 26 (V28) 2. From week 22 (V24) to week 26 (V28) 3.-5. From baseline week 0 (V2) to week 31 (V30) 6.-7. From week 22 (V24) to week 26 (V28) 8. From week 24 (V26) to week 26 (V28) 9. From baseline week 0 (V2) to week 26 (V28) |
1. Dalla settimana 0 (V2) (valore basale) alla settimana 26 (V28) 2. Dalla settimana 22 8V24) alla settimana 26 (V28) 3-5. Dalla settimana 0 (V2) (valore basale) alla settimana 31 (V30) 6-7. Dalla settimana 22 (V24) alla settimana 26 (V28) 8. Dalla settimana 24 (V26) alla settimana 26 (V28) 9. Dalla settimana 0 (V2) (valore basale) alla settimana 26 (V28) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Trattamento adattato per raggiungere il target |
Treat-to-target design |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
India |
Japan |
Mexico |
Russian Federation |
United States |
Finland |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
LVLS, Last Visit Last Subject, ultima visita dell'ultimo paziente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 6 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 6 |